CGRP-targeted migraine treatments are gaining better access as prescriptions. The first drug introduced is nearing insurance benefit listing and the second drug is landing in general hospitals.

According to industry sources, the Calcitonin gene-related peptide (CGRP)-targeted migraine treatment ‘Emgality (galcanezumab)’ has passed deliberations by the Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee on the 12th.

The latecomer ‘Ajovy (fremanezumab)’ also applied for insurance benefits earlier this year but was not set for deliberations in the recent DREC meeting. However still, Ajovy passed the drug committees (DCs) of Seoul Asan Medical Cente